Bicycle Therapeutics (BCYC) Current Deferred Revenue (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Current Deferred Revenue data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 77.68% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (down 77.68% YoY), and the FY2025 full-year result was $3.0 million, down 97.09% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $2.8 million, down from $3.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $135.2 million in Q4 2023 and bottomed at $1.2 million in Q2 2022.
• The 5-year median for Current Deferred Revenue is $12.5 million (2025), against an average of $26.0 million.
• The widest annual swing landed in 2023, when Current Deferred Revenue jumped 1726.95%; it then plunged 97.09% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $7.4 million in 2022, then surged by 1726.95% to $135.2 million in 2023, then fell by 24.81% to $101.7 million in 2024, then slumped by 97.09% to $3.0 million in 2025, then declined by 5.61% to $2.8 million in 2026.
• The last three Current Deferred Revenue figures came in at $2.8 million (Q1 2026), $3.0 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.

Peer Comparison